Rezaee Mehdi, Honari Hossein, Kooshk Mohammad Reza Ashrafi
Faculty of Basic Sciences, Biology Research Center, Imam Hossein University, Tehran, Iran.
Mol Biol Rep. 2014;41(4):2445-52. doi: 10.1007/s11033-014-3099-4. Epub 2014 Jan 16.
Anthrax is common disease between human and animals caused by Bacillus anthracis. The cell binding domain of protective antigen (PAD4) and the binding domain of lethal factor (LFD1) have high immunogenicity potential and always were considered as a vaccine candidate against anthrax. The aims of this study are cloning and expressing of PAD4 and LFD1 in Escherichia coli, purification of the recombinant proteins and determination of their immunogenicity through evaluating of the relative produced polyclonal antibodies in mice. PAD4 and LFD1 genes were cloned in pET28a(+) vector and expressed in E. coli Bl21(DE3)PlysS. Expression and purification of the two recombinant proteins were confirmed by SDS-PAGE and Western blotting techniques. The PAD4 and LFD1 were purified using Ni(+)-NTA affinity chromatography (95-98 %), yielding 37.5 and 45 mg/l of culture, respectively. The antigens were injected three times into mice and production of relative antibodies was evaluated by ELISA test. The results showed that both PAD4 and LFD1 are immunogenic, but LFD1 has higher potential to stimulate Murine immune system. With regard to the high level of LFD1 and PAD4 expression and also significant increment in produced polyclonal antibodies, these recombinant proteins can be considered as a recombinant vaccine candidate against anthrax.
炭疽病是由炭疽芽孢杆菌引起的人和动物共患的常见疾病。保护性抗原(PAD4)的细胞结合结构域和致死因子(LFD1)的结合结构域具有很高的免疫原性潜力,一直被视为抗炭疽疫苗的候选物。本研究的目的是在大肠杆菌中克隆和表达PAD4和LFD1,纯化重组蛋白,并通过评估小鼠体内产生的相关多克隆抗体来测定它们的免疫原性。将PAD4和LFD1基因克隆到pET28a(+)载体中,并在大肠杆菌BL21(DE3)PlysS中表达。通过SDS-PAGE和Western印迹技术确认了两种重组蛋白的表达和纯化。使用Ni(+)-NTA亲和层析法纯化PAD4和LFD1(纯度为95%-98%),每升培养物分别产生37.5毫克和45毫克。将抗原注射到小鼠体内三次,并通过ELISA试验评估相关抗体的产生。结果表明,PAD4和LFD1均具有免疫原性,但LFD1刺激小鼠免疫系统的潜力更高。鉴于LFD1和PAD4的高水平表达以及产生的多克隆抗体显著增加,这些重组蛋白可被视为抗炭疽重组疫苗的候选物。